The Cardiac and Vascular Company segment is dedicated to developing and delivering innovative solutions for cardiovascular and endovascular interventions. This segment focuses on a comprehensive portfolio of products, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and intravascular ultrasound systems. R&D efforts are directed towards enhancing stent technology, improving catheter navigation, and developing advanced imaging modalities for precise diagnostics and treatment planning. These technologies aim to improve patient outcomes by minimizing invasiveness, reducing complications, and enhancing the efficacy of cardiovascular procedures. The segment also explores opportunities in treating cerebral aneurysms and ischemic stroke with specialized coils, stents, aspiration catheters, and clot retrievers. Future growth potential lies in expanding the application of minimally invasive techniques and personalized approaches to cardiovascular care.

The General Hospital Company segment provides a broad range of products and services for hospital settings, focusing on enhancing patient safety and improving clinical workflows. This includes infusion pumps, syringe pumps, solution sets, syringes, I.V. solutions, pain management products, nutritious food, adhesion barriers, blood glucose monitoring systems, blood pressure monitors, and digital thermometers. A key area of focus is contract manufacturing of prefilled syringes and devices for pharmaceutical companies, ensuring precise drug delivery and reducing medication errors. R&D efforts are concentrated on developing smart infusion systems, advanced drug delivery technologies, and user-friendly monitoring devices. The segment aims to improve patient comfort, reduce hospital-acquired infections, and optimize medication management. Future opportunities include expanding digital health solutions for remote patient monitoring and personalized care.

The Blood and Cell Technologies Company segment is dedicated to advancing blood safety and cell therapy solutions. This segment offers a comprehensive portfolio of products, including blood bags, component collection systems, automated blood processing systems, pathogen reduction technology, centrifugal apheresis systems, and cell expansion systems. R&D efforts are focused on developing innovative technologies for blood collection, processing, and storage, as well as advanced cell culture and expansion systems for cell-based therapies. These technologies aim to improve the safety and availability of blood products, enhance the efficiency of cell therapy manufacturing, and expand the application of regenerative medicine. The segment also explores opportunities in developing personalized cell therapies for cancer and autoimmune diseases. Future growth potential lies in expanding the use of automated systems and closed-loop processes to ensure the quality and consistency of blood and cell products.